Aldosterone and mineralocorticoid receptors in the cardiovascular system
- PMID: 20226957
- DOI: 10.1016/j.pcad.2009.12.003
Aldosterone and mineralocorticoid receptors in the cardiovascular system
Abstract
Aldosterone is currently thought to exert its physiologic effects by activating epithelial mineralocorticoid receptors, and its pathologic effects on the cardiovascular system via mineralocorticoid receptors in the heart and blood vessels. Recent studies have extended this understanding to include a reevaluation of the roles of aldosterone and mineralocorticoid receptor activation in blood pressure control; the rapid, nongenomic effects of aldosterone; the role of cortisol as a mineralocorticoid receptor agonist under conditions of redox change/tissue damage/reactive oxygen species generation; the growing consensus that primary aldosteronism accounts for approximately 10% of all essential hypertension; recent new insights into the cardioprotective role of spironolactone; and the development of third- and fourth-generation mineralocorticoid receptor antagonists for use in cardiovascular and other inflammatory disease. These findings on aldosterone action and mineralocorticoid receptor blockade are analyzed in the context of the prevention and treatment of cardiovascular disease.
Copyright 2010. Published by Elsevier Inc.
Similar articles
-
Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system.Steroids. 2005 May-Jun;70(5-7):347-51. doi: 10.1016/j.steroids.2005.02.004. Epub 2005 Mar 24. Steroids. 2005. PMID: 15862816 Review.
-
Aldosterone target organ protection by eplerenone.Mol Cell Endocrinol. 2004 Mar 31;217(1-2):229-38. doi: 10.1016/j.mce.2003.10.047. Mol Cell Endocrinol. 2004. PMID: 15134822 Review.
-
RALES, EPHESUS and redox.J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):121-5. doi: 10.1016/j.jsbmb.2004.12.010. Epub 2005 Jan 28. J Steroid Biochem Mol Biol. 2005. PMID: 15860254 Clinical Trial.
-
Reconsidering the roles of the mineralocorticoid receptor.Hypertension. 2009 Feb;53(2):286-90. doi: 10.1161/HYPERTENSIONAHA.108.119966. Epub 2009 Jan 12. Hypertension. 2009. PMID: 19139379 Review. No abstract available.
-
Aldosterone receptor antagonists.Ann Endocrinol (Paris). 2021 Jun;82(3-4):179-181. doi: 10.1016/j.ando.2020.03.009. Epub 2020 May 27. Ann Endocrinol (Paris). 2021. PMID: 32473789 Review.
Cited by
-
What We Know about and What Is New in Primary Aldosteronism.Int J Mol Sci. 2024 Jan 11;25(2):900. doi: 10.3390/ijms25020900. Int J Mol Sci. 2024. PMID: 38255973 Free PMC article. Review.
-
New medical therapies for heart failure.Nat Rev Cardiol. 2015 Dec;12(12):730-40. doi: 10.1038/nrcardio.2015.137. Epub 2015 Sep 29. Nat Rev Cardiol. 2015. PMID: 26416006 Review.
-
Mineralocorticoid receptors modulate vascular endothelial function in human obesity.Clin Sci (Lond). 2013 Dec;125(11):513-20. doi: 10.1042/CS20130200. Clin Sci (Lond). 2013. PMID: 23786536 Free PMC article. Clinical Trial.
-
Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity.J Physiol. 2014 Apr 15;592(8):1731-44. doi: 10.1113/jphysiol.2013.267609. Epub 2014 Feb 17. J Physiol. 2014. PMID: 24535442 Free PMC article. Review.
-
Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor.Int J Hypertens. 2011;2011:346985. doi: 10.4061/2011/346985. Epub 2011 May 22. Int J Hypertens. 2011. PMID: 21747976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical